RecruitingNot ApplicableNCT06225050

M-2018-334 in Hematological Malignancies

A Single-center Pilot Study Using TCRα/β and CD45RA Depleted Stem Cell Grafts From Haploidentical Donors for Hematopoietic Cell Transplantation in Adults(HAPLO2022)

Sponsor

Miltenyi Biomedicine GmbH

Enrollment

18 participants

Start Date

Aug 21, 2026

Study Type

INTERVENTIONAL

Conditions

Hematological Malignancies

Summary

This is a single-center, open-label, single-arm, pilot clinical study using TCRα/β and CD45RA depleted stem cell grafts from haploidentical donors for hematopoietic cell transplantation in 12 to 18 adult patients.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a medical device called CliniMACS Prodigy® LP-TCRα/β-19-45RA (Trial Version) for people with hematological malignancies. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICECliniMACS Prodigy® LP-TCRα/β-19-45RA (Trial Version)

PBSC grafts from haploidentical donors depleted of TCRaβ+ cells and CD45RA+ cells using CliniMACS Prodigy® will be infused into patients intravenously (IV)

Locations(1)

City of Hope

Duarte, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06225050

Related Trials

A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT0463455278 locations

A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies

NCT072206166 locations

Chlorophyllin for Reducing Oral Mucositis in Total Body Irradiation Prior to Transplant

NCT077091951 location

To Study Lower Dose of Cyclophosphamide After Stem Cell Transplant for Blood Cancers

NCT077199462 locations

Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies

NCT0665263311 locations